Drug Discovery Alliances in India-Indications, Targets, and New Chemical Entities

被引:5
|
作者
Differding, Edmond [1 ]
机构
[1] Differding Consulting Sprl, B-1348 Louvain, Belgium
关键词
drug discovery; Indian biotechnology; medicinal chemistry; research alliance; POTENT; ANTAGONISTS; INHIBITORS; CHINA;
D O I
10.1002/cmdc.201300341
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Global pharmaceutical and biotechnology companies have been building increasingly on the skills and services offered by Indian biotech companies through strategic collaborative partnerships and alliances to fuel their in-house discovery and development pipelines. With the exception of generic press releases, however, very little has been published on the process and progress of drug discovery itself, such as the targets or modes of action involved, nor on the scientific output of such collaborations, and therefore on new chemical entities coming out of India through research collaborations. This Essay provides an analytical review of recent patents, patent applications, and peer-reviewed publications of major research alliances. It aims at highlighting their scientific output as well as the considerable bandwidth of targets and therapeutic areas involved.
引用
收藏
页码:43 / 60
页数:18
相关论文
共 22 条
  • [21] Colworth prize lecture 2016: exploiting new biological targets from a whole-cell phenotypic screening campaign for TB drug discovery
    Moynihan, Patrick Joseph
    Besra, Gurdyal S.
    MICROBIOLOGY-SGM, 2017, 163 (10): : 1385 - 1388
  • [22] Catalyst free, C-3 functionalization of imidazo[1,2-a]pyridines to rapidly access new chemical space for drug discovery efforts
    Gunaganti, Naresh
    Kharbanda, Anupreet
    Lakkaniga, Naga Rajiv
    Zhang, Lingtian
    Cooper, Rose
    Li, Hong-yu
    Frett, Brendan
    CHEMICAL COMMUNICATIONS, 2018, 54 (92) : 12954 - 12957